66 search results for cancer
| # | SuperPathway Name | Genes Count | Relevance Score | |||||
|---|---|---|---|---|---|---|---|---|
| 1 | TGFBR1 KD Mutants in Cancer | 10 | 1.433 | |||||
|
||||||||
| 2 | Signaling by EGFR in Cancer | 28 | 1.331 | |||||
|
||||||||
| 3 | Endometrial cancer | 201 | 1.216 | |||||
|
||||||||
| 4 | SMAD2/3 MH2 Domain Mutants in Cancer | 3 | 1.216 | |||||
|
||||||||
| 5 | Loss of function of TP53 in cancer due to loss of tetramerization ability | 1 | 1.079 | |||||
|
||||||||
| 6 | Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | 5 | 1.079 | |||||
|
||||||||
| 7 | Androgen receptor network in prostate cancer | 105 | 1.079 | |||||
|
||||||||
| 8 | Signaling by ALK in cancer | 55 | 1.079 | |||||
|
||||||||
| 9 | Small cell lung cancer | 96 | 0.900 | |||||
|
||||||||
| 10 | NRP1-triggered signaling pathways in pancreatic cancer | 53 | 0.900 | |||||
|
||||||||
| 11 | Signaling by Overexpressed Wild-Type EGFR in Cancer | 24 | 0.900 | |||||
|
||||||||
| 12 | Apoptosis-related network due to altered Notch3 in ovarian cancer | 52 | 0.900 | |||||
|
||||||||
| 13 | Metabolic reprogramming in colon cancer | 42 | 0.900 | |||||
|
||||||||
| 14 | Breast cancer pathway | 199 | 0.900 | |||||
|
||||||||
| 15 | Cancer immunotherapy by CTLA4 blockade | 15 | 0.900 | |||||
|
||||||||
| 16 | Cancer immunotherapy by PD-1 blockade | 23 | 0.900 | |||||
|
||||||||
| 17 | Constitutive Signaling by AKT1 E17K in Cancer | 38 | 0.900 | |||||
|
||||||||
| 18 | Model for regulation of MSMP expression in cancer cells and its proangiogenic role in ovarian tumors | 3 | 0.900 | |||||
|
||||||||
| 19 | miRNA regulation of p53 pathway in prostate cancer | 32 | 0.900 | |||||
|
||||||||
| 20 | Folate-alcohol and cancer pathway hypotheses | 9 | 0.900 | |||||
|
||||||||
| 21 | Gastric cancer network 2 | 31 | 0.900 | |||||
|
||||||||
| 22 | Interactions of natural killer cells in pancreatic cancer | 27 | 0.900 | |||||
|
||||||||
| 23 | Glucose metabolism in triple-negative breast cancer cells | 8 | 0.900 | |||||
|
||||||||
| 24 | Methotrexate Pathway (Cancer Cell), Pharmacodynamics and Pharmacokinetics | 34 | 0.900 | |||||
|
||||||||
| 25 | MicroRNA for targeting cancer growth and vascularization in glioblastoma | 7 | 0.900 | |||||
|
||||||||
| 26 | Epithelial to mesenchymal transition in colorectal cancer | 161 | 0.900 | |||||
|
||||||||
| 27 | Immune infiltration in pancreatic cancer | 39 | 0.900 | |||||
|
||||||||
| 28 | Neural crest cell migration in cancer | 34 | 0.900 | |||||
|
||||||||
| 29 | Signaling by FGFR3 fusions in cancer | 1 | 0.900 | |||||
|
||||||||
| 30 | Integrated breast cancer pathway | 150 | 0.900 | |||||
|
||||||||
| 31 | Bladder cancer | 40 | 0.900 | |||||
|
||||||||
| 32 | MAPK pathway in congenital thyroid cancer | 11 | 0.900 | |||||
|
||||||||
| 33 | Cell interactions of the pancreatic cancer microenvironment | 28 | 0.900 | |||||
|
||||||||
| 34 | Retinoblastoma gene in cancer | 86 | 0.900 | |||||
|
||||||||
| 35 | T cell modulation in pancreatic cancer | 45 | 0.900 | |||||
|
||||||||
| 36 | Senescence and autophagy in cancer | 105 | 0.900 | |||||
|
||||||||
| 37 | Gastric cancer network 1 | 29 | 0.900 | |||||
|
||||||||
| 38 | Metabolic reprogramming in pancreatic cancer | 42 | 0.900 | |||||
|
||||||||
| 39 | Deregulation of Rab and Rab effector genes in bladder cancer | 16 | 0.900 | |||||
|
||||||||
| 40 | Colorectal Cancer Metastasis | 165 | 0.900 | |||||
|
||||||||
| 41 | TGF-beta receptor signaling activates SMADs | 46 | 0.863 | |||||
|
||||||||
| 42 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 74 | 0.748 | |||||
|
||||||||
| 43 | EML4 and NUDC in mitotic spindle formation | 248 | 0.620 | |||||
|
||||||||
| 44 | ncRNAs involved in STAT3 signaling in hepatocellular carcinoma | 18 | 0.620 | |||||
|
||||||||
| 45 | Signaling by Rho GTPases | 722 | 0.620 | |||||
|
||||||||
| 46 | RhoA signaling pathway | 36 | 0.620 | |||||
|
||||||||
| 47 | pyrimidine deoxyribonucleotides biosynthesis from CTP | 16 | 0.620 | |||||
|
||||||||
| 48 | Cytoskeletal Signaling | 308 | 0.620 | |||||
|
||||||||
| 49 | Pyrimidine metabolism | 85 | 0.620 | |||||
|
||||||||
| 50 | Signal Transduction | 2590 | 0.620 | |||||
|
||||||||
| 51 | Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 88 | 0.611 | |||||
|
||||||||
| 52 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 135 | 0.611 | |||||
|
||||||||
| 53 | TP53 Regulates Transcription of Cell Cycle Genes | 48 | 0.432 | |||||
|
||||||||
| 54 | NOTCH2 Activation and Transmission of Signal to the Nucleus | 50 | 0.432 | |||||
|
||||||||
| 55 | Transport of inorganic cations/anions and amino acids/oligopeptides | 728 | 0.432 | |||||
|
||||||||
| 56 | CTNNB1 S33 mutants aren't phosphorylated | 58 | 0.432 | |||||
|
||||||||
| 57 | Transcriptional Regulation by MECP2 | 62 | 0.432 | |||||
|
||||||||
| 58 | ERK Signaling | 1185 | 0.432 | |||||
|
||||||||
| 59 | Doxorubicin Pathway, Pharmacokinetics | 28 | 0.432 | |||||
|
||||||||
| 60 | serine and glycine biosynthesis | 18 | 0.432 | |||||
|
||||||||
| 61 | Prolactin Signaling | 432 | 0.432 | |||||
|
||||||||
| 62 | GPCR Pathway | 712 | 0.432 | |||||
|
||||||||
| 63 | MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement | 21 | 0.432 | |||||
|
||||||||
| 64 | PPAR signaling pathway | 69 | 0.432 | |||||
|
||||||||
| 65 | ncRNAs involved in Wnt signaling in hepatocellular carcinoma | 220 | 0.432 | |||||
|
||||||||
| 66 | Signaling by ERBB2 KD Mutants | 29 | 0.432 | |||||
|
||||||||